gamenftfreeplaytoearn| Shengnuo Pharmaceutical Dai Xiaochang resigns as chief strategy officer: continues to serve as executive director and serves as drug development consultant

News summary

Shengnuo Pharmaceuticals-B(02257gamenftfreeplaytoearn.HK) Chief Strategy Officer Dai Xiaochang resigned privately on May 17, but remained as an executive director and was appointed as a senior consultant for the group's drug development and commercialization.

Newsletter text

[Dai Xiaochang, chief strategy officer of Shengnuo Pharmaceuticals, leaves office] On May 17, Shengnuo Pharmaceuticals (stock code: 02257.HK) issued an announcement stating that Dai Xiaochang decided to resign as chief strategy officer due to personal reasons. The decision will take effect from the day of the announcement.

Dai Xiaochang continued to serve as executive director and agreed to serve as a member of the group's drug development and commercializationgamenftfreeplaytoearnsenior consultant. This move is regarded as another important measure by the company in strategic adjustment and talent layout.